Leveragen Inc., a Boston-based biotech company, announced a strategic collaboration with Moonlight Bio, a Seattle-based biotech company, to develop advanced T cell therapies targeting challenging and difficult-to-treat cancers. The partnership aims to integrate Leveragen’s proprietary Singularity Sapiens Mouse platform with Moonlight Bio’s expertise in T cell engineering to create T cell therapies with enhanced functionality, persistence, and efficacy.